These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23820820)

  • 21. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
    Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3.
    Araujo J; Breuer P; Dieringer S; Krauss S; Dorn S; Zimmermann K; Pfeifer A; Klockgether T; Wuellner U; Evert BO
    Hum Mol Genet; 2011 Aug; 20(15):2928-41. PubMed ID: 21536589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3.
    Nobre RJ; Lobo DD; Henriques C; Duarte SP; Lopes SM; Silva AC; Lopes MM; Mariet F; Schwarz LK; Baatje MS; Ferreira V; Vallès A; Pereira de Almeida L; Evers MM; Toonen LJA
    Nucleic Acid Ther; 2022 Jun; 32(3):194-205. PubMed ID: 34878314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
    McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
    Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells.
    Konno A; Shuvaev AN; Miyake N; Miyake K; Iizuka A; Matsuura S; Huda F; Nakamura K; Yanagi S; Shimada T; Hirai H
    Cerebellum; 2014 Feb; 13(1):29-41. PubMed ID: 23955261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
    Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
    Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
    Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
    Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.
    Evert BO; Vogt IR; Vieira-Saecker AM; Ozimek L; de Vos RA; Brunt ER; Klockgether T; Wüllner U
    J Neuropathol Exp Neurol; 2003 Oct; 62(10):1006-18. PubMed ID: 14575237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.
    Schuster KH; Zalon AJ; DiFranco DM; Putka AF; Stec NR; Jarrah SI; Naeem A; Haque Z; Zhang H; Guan Y; McLoughlin HS
    Mol Ther; 2024 May; 32(5):1359-1372. PubMed ID: 38429929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.
    Zeng L; Wang B; Merillat SA; Minakawa EN; Perkins MD; Ramani B; Tallaksen-Greene SJ; Costa MDC; Albin RL; Paulson HL
    Neurobiol Dis; 2015 Oct; 82():281-288. PubMed ID: 26141599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.
    Jung J; Xu K; Lessing D; Bonini NM
    Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
    Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
    Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
    Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
    J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward understanding Machado-Joseph disease.
    Costa Mdo C; Paulson HL
    Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compromised mitochondrial complex II in models of Machado-Joseph disease.
    Laço MN; Oliveira CR; Paulson HL; Rego AC
    Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
    Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
    PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered expression of carbonic anhydrase-related protein XI in neuronal cells expressing mutant ataxin-3.
    Hsieh M; Chang WH; Hsu CF; Nishimori I; Kuo CL; Minakuchi T
    Cerebellum; 2013 Jun; 12(3):338-49. PubMed ID: 23184527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
    Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW
    Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
    Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
    J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.